Gilead Sciences (GILD) Shares Sold by Pendal Group Ltd

Pendal Group Ltd trimmed its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 43.8% during the first quarter, HoldingsChannel reports. The institutional investor owned 175,696 shares of the biopharmaceutical company’s stock after selling 137,202 shares during the quarter. Pendal Group Ltd’s holdings in Gilead Sciences were worth $13,246,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Heritage Wealth Advisors lifted its position in Gilead Sciences by 2.5% during the fourth quarter. Heritage Wealth Advisors now owns 26,523 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 642 shares in the last quarter. Hanson & Doremus Investment Management lifted its position in shares of Gilead Sciences by 35.7% during the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 648 shares in the last quarter. Griffin Asset Management Inc. lifted its position in shares of Gilead Sciences by 2.5% during the fourth quarter. Griffin Asset Management Inc. now owns 27,160 shares of the biopharmaceutical company’s stock worth $1,946,000 after purchasing an additional 650 shares in the last quarter. First Capital Advisors Group LLC. lifted its position in shares of Gilead Sciences by 9.1% during the fourth quarter. First Capital Advisors Group LLC. now owns 7,857 shares of the biopharmaceutical company’s stock worth $563,000 after purchasing an additional 653 shares in the last quarter. Finally, Wedbush Securities Inc. lifted its position in shares of Gilead Sciences by 1.0% during the fourth quarter. Wedbush Securities Inc. now owns 65,102 shares of the biopharmaceutical company’s stock worth $4,664,000 after purchasing an additional 660 shares in the last quarter. 78.16% of the stock is currently owned by hedge funds and other institutional investors.

GILD stock opened at $68.02 on Friday. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.84 and a quick ratio of 2.75. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54. The firm has a market cap of $87.90 billion, a price-to-earnings ratio of 7.95, a price-to-earnings-growth ratio of -5.88 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.40 billion. During the same quarter in the previous year, the firm earned $2.23 EPS. The firm’s revenue for the quarter was down 21.8% on a year-over-year basis. equities research analysts predict that Gilead Sciences will post 5.75 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 annualized dividend and a yield of 3.35%. Gilead Sciences’s payout ratio is 26.64%.

In other Gilead Sciences news, CFO Robin L. Washington sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the sale, the chief financial officer now owns 23,749 shares in the company, valued at $1,907,282.19. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director John Francis Cogan sold 5,836 shares of the business’s stock in a transaction on Friday, May 4th. The shares were sold at an average price of $65.09, for a total transaction of $379,865.24. Following the sale, the director now owns 58,455 shares of the company’s stock, valued at approximately $3,804,835.95. The disclosure for this sale can be found here. In the last quarter, insiders have sold 241,102 shares of company stock valued at $18,237,884. 1.30% of the stock is owned by insiders.

A number of research firms have recently commented on GILD. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. BidaskClub cut shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Morgan Stanley reduced their target price on shares of Gilead Sciences from $85.00 to $81.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 2nd. Finally, Barclays reduced their target price on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average target price of $88.14.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply